Viktig sikkerhets- og forskrivningsinformasjon
Recommended treatment modifications for Opdualag1
Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0
(NCI-CTCAE v5).
aRecommendation for the use of hormone replacement therapy is provided in SmPC
bThe safety of re-initiating Opdualag in patients previously experiencing immune-related myocarditis is not known.
Reference:
1425-NO-2500004 February 2025
We refer to the SmPC for full information on Opdualag®